| Abstract |
【Abstract】Objective To investigate the effect of butylphthalide combined with piracetam in the treatment of patients with cognitive dysfunction after stroke. Methods 127 patients with post-stroke cognitive dysfunction admitted to our department from December 2018 to September 2020 were selected and divided into groups by coin tossing. 63 patients in the control group were given piracetam, and 64 patients in the observation group were given butylphthalide Soft capsule, compare the neurological function, brain neurotransmitter, cognitive function and adverse reactions between the two groups. Results After treatment, the levels of the National Institutes of Health Stroke Scale (NIHSS), central nervous system specific protein (S100B), and neuron-specific enolase (NSE) levels in the two groups were lower than before treatment. The two groups of serotonin (5-hydroxytryptamine) HT), dopamine (DA), norepinephrine (NE) levels, and Mini Mental State Examination Scale (MMSE) scores were all higher than before treatment, and the observation group was better than the control group (P<0.05). The incidence of adverse reactions in the control group was 3.13%, and the incidence of adverse reactions in the observation group was 6.35% (P>0.05). Conclusion Butylphthalide combined with piracetam in the treatment of patients with cognitive dysfunction after stroke has a satisfactory effect, significantly improves the patients neurological and cognitive functions, reduces S100B, NSE levels, and increases 5-HT, DA, NE levels, and is safe high.
|